Phase 3 Study of Recurrent Metastatic HNSCC with KEYTRUDA

As of June 11, 2019, Merck’s KEYTRUDA is now FDA approved for first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma as monotherapy for patients whose tumors express PD-L1 (CPS ≥1) or in combination with platinum and fluorouracil (FU) regardless of PD-L1 expression. Returning guest Dr. Danny Rischin, Director of the Department of Medical Oncology, Peter MacCallum Cancer Centre (Melbourne, Australia) discusses the final analysis of the Phase 3 KEYNOTE-048, KEYTRUDA study, which was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

Read More

Chiropractic Care and Studies on Stroke

Dr. Gerard Clum, D.C., Board Member of the Foundation for Chiropractic Progress, addresses the issues surrounding neck manipulation and strokes. There have been numerous medical studies showing there is no causal link between strokes and chiropractic care. The latest study, published in the Annals of Medicine on April 6, 2019, concludes that “manual therapy does not result in an increased risk of cervical artery dissection or CAD.

Read More

The Center for Innovative GYN Care

Dr. Paul MacKoul, one of the founders of The Center for Innovative GYN Care® (CIGC), discusses recent research that showed complex GYN issues are going undiagnosed among women around the world. The study, conducted by CIGC, collected 5 years of data from over 1,500 hysterectomy patients and nearly 1 thousand myomectomy patients who had surgeries at CIGC. He also talks about the laparoscopy techniques, DualPortGYN® and LAAM-BUAO® that have been perfected by CIGC.

Read More

SysAid Technologies ITSM

Doron Youngerwood, Director of Marketing at SysAid® Technologies, discusses their IT service management (ITSM) solution software that provides a suite of tools that increases efficiency and improves patient care.

Read More